| 摘要: |
| ［目的］比较两组治疗拉米夫定耐药的慢性乙型肝炎的方案的有效性及经济性。［方法］选择门诊拉米夫定耐药的慢性乙型肝炎患者150例，A组75例，给予恩替卡韦（ETV）0.5 mg，口服1次/d；B组75例，给予阿德福韦酯（ADV）10 mg及拉米夫定（LAM）100 mg，口服1次/d。观察两组治疗效果，并采用最小成本法分析。［结果］在HBV-DNA转阴率和ALT复常率等效果方面，两组差异无显著性意义（P>0.05），A组成本为13101元；B组成本为12382元。［结论］即时疗效分析两组相似，但从最小成本分析角度上看阿德福韦酯联合拉米夫定优于单用恩替卡韦方案。 |
| 关键词: 耐拉米夫定的慢性乙型肝炎 恩替卡韦 阿德福韦酯 最小成本分析 |
| DOI：10.11724/jdmu.2011.05.20 |
| 分类号:R978.7；R969.4；R956 |
| 基金项目: |
|
| Cost-minimization analyses on the medication of lamivudine-resistant chronic hepatitis B |
|
ZHOU Yan-mei1, FAN Guang-jun2, HUANG Jun-zi2, MU Li2, DAI Lin-na3
|
|
1.Department of Pharmacy,The People`s Hospital of Jianyang City,Jianyang 641400,China;2.Department of Pharmacy,the Second Affiliated Hospital of Dalian Medical University,Dalian 116027,China;3.College of Pharmacy,Dalian Medical University,Dalian 116044,China
|
| Abstract: |
| ［Objective］To study the validity and affordability between two ways in the treatment of lamivudine-resistant chronic hepatitis B.［Methods］One hundred and fifty patients with lamivudine-resistant chronic hepatitis B selected from clinic service were divided into group A and group B.Seventy-five patients in group A were treated with oral entecavir 0.5mg/d,and 75 patients in group B were treated with oral adefovir dipivoxil 10 mg/d and lamivudine 100 mg/d.The therapeutic efficacy was monitored and the cost-minimization analyses were performed.［Results］There was no significant difference in the HBV-DNA negative rates and the ALT normalization rates between the two groups (P>0.05).The treatment cost was 13,101 Yuan in group A and 12,382 Yuan in group B.［Conclusion］The combination of ADV with LAM is better than ETV used alone in cost-effectiveness ratio in the treatment of lamivudine-resistant chronic hepatitis B. |
| Key words: lamivudine-resistant chronic hepatitis B Entecavir Adefovir dipivoxil cost-minimization analysis |
